Abstract
The ability to anticipate changes in blood glucose (BG) concentration would have a great impact on Type 1 diabetics (T1D). In order to create T1D treatment plans, patients collect a BG concentration time series. It has been demonstrated that various types of recurrent neural networks, such as Long Short Term Memory (LSTM), have success forecasting T1D BG concentrations. However, limited work has been done to characterize the T1D time series or set limits on neural network’s predictive capacity. In this work, a T1D patient’s 14 day BG concentration time series is studied. First, I test the time series stationarity. Then I use auto-correlation analysis, spectral analysis, and Gaussian process regression to characterize the T1D BG time series. Finally, the LSTM’s prediction quality is quantified and interpreted at different prediction intervals. The success or failure of the LSTM’s predictions are interpreted using the characterization of the time series.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was not funded by any third party.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Office of Regulatory Affairs: Human Research Protection Program MSU Study ID: STUDY00004671 Principal Investigator: Julie C Libarkin Category: Exempt 98 Exempt Determination Date: 7/23/2020 Limited IRB Review: Not Required. Title: Setting limits on neural network's predictive capacity in T1D blood glucose concentration This study has been determined to be exempt under 45 CFR 46.104(d) 98.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Transparency is of the utmost importance, data and analysis code are both available upon request. Please contact chunatho{at}msu.edu
